- Nyrada (NYR) receives a new US patent for its cholesterol lowering program
- The patent provides protection for Nyrada’s intellectual property (IP) relating to its inhibitor technology in the US and is valid until 16 March 2038
- The company says recent studies show its lead drug candidate demonstrates a 46 per cent reduction in total cholesterol when given as a monotherapy, and a 65 per cent reduction when dosed in combination with the leading statin drug, Lipitor
- Nyrada shares are trading up 4.92 per cent at 32 cents at 10:30 am AEST
Nyrada (NYR) has been granted a new US patent for its cholesterol lowering program.
The new patent, entitled “Heterocyclic Inhibitors of PCSK9”, was granted by the US Patent and Trademark Office and marks the first patent for the company’s cholesterol series.
The patent provides protection for Nyrada’s intellectual property (IP) relating to its PCSK9 inhibitor technology in the US and is valid until 16 March 2038.
Nyrada’s Chief Executive Officer James Bonnar said the US presented a large market of 19.4 million adults unable to achieve a healthy cholesterol level, despite taking statin therapy. Nyrada aims to remedy this with its single pill.
“Our PCSK9 inhibitor technology is being developed as an oral treatment that can be taken as a monotherapy, or in combination with a statin as a single pill,” Mr Bonnar said.
“Having patent protection in place significantly strengthens our business development position for this innovative technology.”
The company said recent in vivo studies showed its lead drug candidate demonstrated a 46 per cent reduction in total cholesterol when given as a monotherapy, and a 65 per cent reduction when dosed in combination with the leading statin drug, Lipitor. This is significantly higher than the 27 per cent reduction achieved using Lipitor alone.
“Further exploratory analysis of this study will be reported as soon as the data becomes available,” Mr Bonnar said.
Nyrada shares are trading up 4.92 per cent at 32 cents at 10:30 am AEST.